SHOULD ANTI-CGRP MONOCLONAL ANTIBODIES ALWAYS BE THE DRUG OF FIRST CHOICE FOR MIGRAINE PROPHYLAXIS IN BRAZIL? - A PHARMACOECONOMIC STUDY DOI

Davy Henrique Sousa Pelliciari,

Caio Ricco Alves Reis,

Carlos Alberto Bordini

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 15(3), P. 170 - 174

Published: Sept. 30, 2024

Efficacy (success of therapy under ideal conditions), efficiency (the relationship between the costs and outcomes a specific intervention), effectiveness balance efficacy in clinical practice) are measures used to evaluate health interventions. Thus, private practice public system, knowledge these pharmacoeconomic data should influence appropriate treatment choice. Migraine prophylaxis falls within this context. Traditional medications available while galcanezumab is not routinely available. The present study aims analyze traditional therapeutic alternatives (amitriptyline, divalproex sodium, topiramate). were obtained from relevant literature (PubMed) cost values ABCFARMA magazine. economic impact analysis considered living for an economically active adult Brazil based on Brazilian Institute Geography Statistics (Instituto Brasileiro de Geografia e Estatística, IBGE) Applied Economic Research Pesquisa Econômica Aplicada, IPEA). Efficacy: amitriptyline: 40%; sodium: 30%; topiramate: 31%; galcanezumab: 50%. Their annual were: amitriptyline R$ 240.00; sodium divalproate 876.00; topiramate 600.00; 13,992.00. Efficiency: 200%; 41.1%; 62%; 4%. Ultimately, 120%; 35.7%; 46.5%; 27%. Galcanezumab most effective; however, broader analysis, where payers, availability, patient conditions considered, evaluating alone may be feasible practical contexts and, therefore, anti-CGRP antibodies will always first-line migraine prophylaxis.

Language: Английский

Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics DOI Creative Commons

Kofi Frimpong-Manson,

Yuma T. Ortiz, Lance Richard McMahon

et al.

Frontiers in Molecular Neuroscience, Journal Year: 2024, Volume and Issue: 17

Published: Feb. 28, 2024

The individual and global burden of migraine is such significance that there are accelerated efforts to develop new therapies. New therapeutics needed address the current deficiencies exist in efficacy adherence rate approved anti-migraine medications. recent discovery calcitonin gene related peptide as an add-on role serotonin has markedly increased range treatment options for acute chronic migraine. Despite this, tackling complexity disorders requires a complete understanding its pathophysiology. Preclinical animal models can shed light on disease-related pathophysiology, including Indeed, use been instrumental developing many therapeutics. However, model limited by predictive face validity model, this extends preclinical models. In review, summary pathophysiology given from both clinical perspective, emphasis placed We will discuss strengths pitfalls common well experimental research areas explore further.

Language: Английский

Citations

9
Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study DOI
Eleonora Colombo, Alberto Doretti,

Renata Rao

et al.

Neurological Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 25, 2025

Language: Английский

Citations

1
SIRT1 activation by Ligustrazine ameliorates migraine via the paracrine interaction of microglia and neurons DOI
Yu Chen, Ziwei Xing, Junren Chen

et al.

Phytomedicine, Journal Year: 2024, Volume and Issue: 135, P. 156069 - 156069

Published: Sept. 17, 2024

Language: Английский

Citations

6
Neuroimmunological effects of omega-3 fatty acids on migraine: a review DOI Creative Commons
Ting‐Bin Chen, Cheng‐Chia Yang, I‐Ju Tsai

et al.

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: May 6, 2024

Migraine is a highly prevalent disease worldwide, imposing enormous clinical and economic burdens on individuals societies. Current treatments exhibit limited efficacy acceptability, highlighting the need for more effective safety prophylactic approaches, including use of nutraceuticals migraine treatment. involves interactions within central peripheral nervous systems, with significant activation sensitization trigeminovascular system (TVS) in pain generation transmission. The condition influenced by genetic predispositions environmental factors, leading to altered sensory processing. neuroinflammatory response increasingly recognized as key event underpinning pathophysiology migraine, involving complex neuro-glio-vascular interplay. This interplay partially mediated neuropeptides such calcitonin gene receptor peptide (CGRP), pituitary adenylate cyclase activating polypeptide (PACAP) and/or cortical spreading depression (CSD) oxidative stress, mitochondrial dysfunction, nucleotide-binding domain-like family pyrin domain containing-3 (NLRP3) inflammasome formation, activated microglia, reactive astrocytes. Omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) docosahexaenoic (DHA), crucial system, mediate various physiological functions. PUFAs offer cardiovascular, neurological, psychiatric benefits due their potent anti-inflammatory, anti-nociceptive, antioxidant, neuromodulatory properties, which modulate neuroinflammation, neurogenic inflammation, transmission, enhance stability, mood regulation. Moreover, specialized pro-resolving mediators (SPMs), class PUFA-derived lipid mediators, regulate pro-inflammatory resolution pathways, playing anti-inflammatory neurological roles, turn may be beneficial alleviating symptomatology migraine. impact neurobiological pathways have demonstrated lack major adverse events, underscoring multifaceted approach management. Although not all omega-3 trials shown reducing further research needed fully establish understand precise molecular mechanisms underlying effects SPMs progression. review highlights potential modulating brain functions, neuroimmunological effects, suggests promise candidates prophylaxis.

Language: Английский

Citations

4
The Impact of Neuroglia on Vestibular Disorders: Insights and Implications DOI Creative Commons
Melissa Castillo‐Bustamante, Andrés Felipe Herrón-Arango,

María José Bedoya

et al.

Neuroglia, Journal Year: 2025, Volume and Issue: 6(1), P. 10 - 10

Published: March 1, 2025

Vestibular disorders significantly affect individuals by impairing balance, spatial orientation, and quality of life. Despite the focus on neuronal mechanisms, emerging research emphasizes importance neuroglia—astrocytes, microglia, oligodendrocytes, Schwann cells—in onset, progression, resolution these conditions. This narrative review explores roles neuroglia in vestibular disorders, including migraines unilateral bilateral vestibulopathies. It discusses established facts, challenges, future perspectives, offering insights into their pathophysiological therapeutic implications, limitations current research. By understanding interplay between function, this aims to advance diagnostic treatment strategies for

Language: Английский

Citations

0
Research Status on the Pathogenesis of Migraine DOI

宇宸 张

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(02), P. 798 - 805

Published: Jan. 1, 2025

Language: Английский

Citations

0
Voltage-gated Calcium Channels as Potential Therapeutic Targets in Migraine DOI
Juliana Geremias Chichorro, Eder Gambeta, Darciane Favero Baggio

et al.

Journal of Pain, Journal Year: 2024, Volume and Issue: 25(8), P. 104514 - 104514

Published: March 24, 2024

Language: Английский

Citations

2
The Role of Neuroglia in Administrating Nerve Blockers and Anesthesia to Patients DOI Creative Commons

Anjali Patel,

Raja Al‐Bahou, Rajvi Thakkar

et al.

Neuroglia, Journal Year: 2024, Volume and Issue: 5(1), P. 13 - 26

Published: Jan. 29, 2024

Dysfunction of the neuroglia can have profound consequences on blood–brain barrier (BBB). Studies shown that disruption astrocytic–endothelial interaction compromise permeability BBB and its effectiveness in selectively regulating exchange substances. Microglia recently been recognized to a significant role initiation chronic pain interactions with various nerve blockers anesthetic agents. resolution via pathway involves Cannabinoid receptor type 2 activation MAP kinase phosphorylation. Understanding these cells context neuropathic neurological disorders aid improving clinical outcomes challenging nature managing pain. Advancing studies proposed pharmacological genetic modulation microglia as potential treatment option for patients

Language: Английский

Citations

0
SHOULD ANTI-CGRP MONOCLONAL ANTIBODIES ALWAYS BE THE DRUG OF FIRST CHOICE FOR MIGRAINE PROPHYLAXIS IN BRAZIL? - A PHARMACOECONOMIC STUDY DOI

Davy Henrique Sousa Pelliciari,

Caio Ricco Alves Reis,

Carlos Alberto Bordini

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 15(3), P. 170 - 174

Published: Sept. 30, 2024

Efficacy (success of therapy under ideal conditions), efficiency (the relationship between the costs and outcomes a specific intervention), effectiveness balance efficacy in clinical practice) are measures used to evaluate health interventions. Thus, private practice public system, knowledge these pharmacoeconomic data should influence appropriate treatment choice. Migraine prophylaxis falls within this context. Traditional medications available while galcanezumab is not routinely available. The present study aims analyze traditional therapeutic alternatives (amitriptyline, divalproex sodium, topiramate). were obtained from relevant literature (PubMed) cost values ABCFARMA magazine. economic impact analysis considered living for an economically active adult Brazil based on Brazilian Institute Geography Statistics (Instituto Brasileiro de Geografia e Estatística, IBGE) Applied Economic Research Pesquisa Econômica Aplicada, IPEA). Efficacy: amitriptyline: 40%; sodium: 30%; topiramate: 31%; galcanezumab: 50%. Their annual were: amitriptyline R$ 240.00; sodium divalproate 876.00; topiramate 600.00; 13,992.00. Efficiency: 200%; 41.1%; 62%; 4%. Ultimately, 120%; 35.7%; 46.5%; 27%. Galcanezumab most effective; however, broader analysis, where payers, availability, patient conditions considered, evaluating alone may be feasible practical contexts and, therefore, anti-CGRP antibodies will always first-line migraine prophylaxis.

Language: Английский

Citations

0